Anti-CD3/Anti-SLAMF7 Bispecific Antibody (University of Virginia)

N/A

Report date: 2026/03/19 17:22:42

Base Information

Drug NameAnti-CD3/Anti-SLAMF7 Bispecific Antibody (University of Virginia)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionT cell surface glycoprotein CD3 inhibitorsAnti-SLAMF7

TargetsT cell surface glycoprotein CD3SLAM family member 7

Therapy Area/IndicationsMultiple Myeloma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesUniversity Of Virginia

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesUniversity Of Virginia

Active IndicationsN/A

Inactive IndicationsMultiple Myeloma

Other Information

ATC CodeN/A